The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
-
Published:2021-07
Issue:1
Volume:100
Page:225-237
-
ISSN:0085-2538
-
Container-title:Kidney International
-
language:en
-
Short-container-title:Kidney International
Author:
Ariceta Gema,
Dixon Bradley P.,
Kim Seong Heon,
Kapur Gaurav,
Mauch Teri,
Ortiz Stephan,
Vallee Marc,
Denker Andrew E.,
Kang Hee Gyung,
Greenbaum Larry A.ORCID,
Lovell Helen,
Muff-Luett Melissa,
Malone Kristin,
Adeagbo Oluwasegun,
Wilkerson Alexandria,
Fraga Gloria,
Sarri Scherezade,
Cheong Hae Il,
Ahn Yo Han,
Han Kyoung Hee
Funder
Alexion Pharmaceuticals
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献